Effects of Midazolam on Brain Injury After Transient Focal Cerebral Ischemia in Rats

Effects of Midazolam on Brain Injury After Transient Focal Cerebral Ischemia in Rats
复制标题

DOI:
10.1097/ana.0b013e318191697a
复制
发表时间:
2009-04-01
影响因子:
3.7
通讯作者:
Kass, Ira S.
Kass, Ira S.
中科院分区:
医学3区
文献类型:
--
作者:
Lei, Baiping;Popp, Susanna;Kass, Ira S.

文献摘要

被引文献

相似文献

苯二氮卓类药物咪达唑仑通常用于存在脑缺血风险的手术室和重症监护室中的镇静和麻醉。因此,我们研究了其减少脑缺血后损伤的能力。将雄性Wistar大鼠随机分为高剂量咪达唑仑组或匹配的溶剂组和低剂量咪达唑仑组或匹配的溶剂组。大鼠大脑中动脉闭塞90分钟。咪达唑仑组于缺血前10 min静脉滴注咪达唑仑10 mg/kg或25 mg/kg,缺血后1 h静脉滴注咪达唑仑5 mg/kg或12.5 mg/kg。在溶剂组中,以相同的时间间隔给予相似体积的溶剂。大小合适。缺血后7天,确定缺血半暗带和核心区域中的NeuN免疫阳性细胞以及神经学结果。与溶剂处理的大鼠相比,高剂量咪达唑仑(25 mg/kg)处理的大鼠的梗死面积较小(93.9 ± 63.5 mm(3)vs. 152.0 ± 53.7 mm(3))。P < 0.05),缺血核心区的NeUN免疫阳性细胞更多(206.7 +/- 211.3/mm(2)vs. 40.0 +/- 66.3/mm(2)。P < 0.01),神经功能预后较好(P
The benzodiazepine, midazolam, is commonly used for sedation and anesthesia in the operating, room and the intensive care unit where there is a risk of cerebral ischemia. We therefore examined its ability to reduce damage subsequent to cerebral ischemia. Male Wistar rats were randomly assigned to a high-dose midazolam group or a matched vehicle group and a lower dose of midazolam group or a matched vehicle group. The rats underwent 90 minutes of middle cerebral artery occlusion. In the midazolam groups, the first dose of midazolam (10 or 25 mg/kg) was given by 10-minute intravenous infusion before ischemia; a second dose of 1/2 the initial dose (5 or 12.5 mg/kg) was given 1 hour after the onset of ischemia. In the vehicle groups, a similar volume of vehicle was given at the same time intervals. Infarct size. NeuN immunopositive cells in the ischemic penumbral and core regions, and neurologic outcome were determined 7 days after ischemia. Compared with vehicle-treated rats, the higher-dose midazolam (25 mg/kg)-treated rats had a smaller infarct size (93.9 +/- 63.5 mm(3) vs. 152.0 +/- 53.7 mm(3). P < 0.05), more NeUN immunopositive cells in the ischemic core region (206.7 +/- 211.3/mm(2) vs. 40.0 +/- 66.3/mm(2). P < 0.01), and better neurologic outcome (P